Invivyd (IVVD)
0.74
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 4 Invivyd, Inc. For: Jul 31 Filed by: Mina Michael
August 4, 2026 4:15 PM - SEC Filing
Form 3 Invivyd, Inc. For: Jul 31 Filed by: Mina Michael
August 4, 2026 4:15 PM - SEC Filing
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2026 7:01 AM - StreetInsider
Form SCHEDULE 13G Invivyd, Inc. Filed by: BlackRock, Inc.
July 28, 2026 4:45 PM - SEC Filing
Form 8-K Invivyd, Inc. For: Jul 23
July 24, 2026 4:05 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
July 8, 2026 6:43 AM - StreetInsider
Form 8-K Invivyd, Inc. For: Jul 06
July 6, 2026 7:12 AM - SEC Filing
FDA notifies Invivyd that Pemgarda EUA will end June 2027
July 6, 2026 7:06 AM - StreetInsider
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
July 6, 2026 7:01 AM - StreetInsider
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026 7:01 AM - StreetInsider
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
June 29, 2026 7:00 AM - Globe NewsWire
INVIVYD completes enrollment in Phase 3 COVID antibody trial
June 16, 2026 7:01 AM - StreetInsider
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
June 16, 2026 7:01 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
June 16, 2026 6:47 AM - StreetInsider
Invivyd begins Phase 3 trial comparing COVID antibody to mRNA vaccine
June 9, 2026 7:01 AM - StreetInsider
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safe
June 9, 2026 7:01 AM - StreetInsider
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2026 7:01 AM - Globe NewsWire
Invivyd completes enrollment in phase 3 COVID antibody trial
June 1, 2026 7:02 AM - StreetInsider
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
June 1, 2026 7:01 AM - StreetInsider
Invivyd to Participate in Upcoming Investor Events
May 27, 2026 7:01 AM - Globe NewsWire
Form 4 Invivyd, Inc. For: May 19 Filed by: Royan Ajay
May 21, 2026 4:50 PM - SEC Filing
Form 4 Invivyd, Inc. For: May 19 Filed by: MCLAUGHLIN KEVIN F
May 21, 2026 4:49 PM - SEC Filing
Form 4 Invivyd, Inc. For: May 19 Filed by: MCGUIRE TERRANCE
May 21, 2026 4:49 PM - SEC Filing
Form 4 Invivyd, Inc. For: May 19 Filed by: M28 Capital Management LP
May 21, 2026 4:48 PM - SEC Filing
Form 4 Invivyd, Inc. For: May 19 Filed by: BOLNO PAUL
May 21, 2026 4:48 PM - SEC Filing
Form 4 Invivyd, Inc. For: May 19 Filed by: Berry Tamsin
May 21, 2026 4:48 PM - SEC Filing
Form 8-K Invivyd, Inc. For: May 19
May 19, 2026 4:05 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
May 19, 2026 6:49 AM - StreetInsider
Form SCHEDULE 13G/A Invivyd, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 4:47 PM - SEC Filing
Form SCHEDULE 13G/A Invivyd, Inc. Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:32 PM - SEC Filing
Form S-8 Invivyd, Inc.
May 14, 2026 4:06 PM - SEC Filing
Form 10-Q Invivyd, Inc. For: Mar 31
May 14, 2026 7:19 AM - SEC Filing
Form 8-K Invivyd, Inc. For: May 14
May 14, 2026 7:13 AM - SEC Filing
Invivyd, Inc. (IVVD) Misses Q1 EPS by 7c
May 14, 2026 7:11 AM - StreetInsider
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 14, 2026 7:01 AM - Globe NewsWire
Full Article List
